Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database

Nieto, Karina; Adams, William; Pham, Nghia H.; Block, Alec M.; Grover, Surbhi; Small, William; Harkenrider, Matthew M.

doi:10.1016/j.ygyno.2017.11.010

Cited by 21 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike stage I and II UCCC, practice patterns are more similar regarding the utilization of adjuvant chemotherapy in women diagnosed with stage III and IV disease. Although a recent NCDB study suggested that adjuvant chemotherapy, when controlling for stage among other variables, did not have a meaningful effect on the survival of patients with UCCC [57], adjuvant chemotherapy is generally offered to patients with advanced stage endometrial cancers making it difficult to compare the outcomes of adjuvant chemotherapy versus no further treatment. It is important to note however that prospective trials dedicated to chemotherapy evaluation in this specific group are lacking.…”

Section: Historical Datamentioning

confidence: 99%

“…Multi-modal therapy has been utilized in randomized clinical trials as well as single and multi-institutional series. One of the largest retrospective evaluations was recently published in which the authors evaluated the use of adjuvant therapy in a group of 4298 women from the NCDB [57]. Outcomes in women undergoing hysterectomy were evaluated based on adjuvant therapy, if any, to include chemotherapy, vaginal cuff brachytherapy, external beam radiation therapy or either type of radiation administered in conjunction with chemotherapy.…”

Section: Historical Datamentioning

confidence: 99%

See 1 more Smart Citation

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation

Olawaiye

Leath

2019

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

Section: Historical Datamentioning

confidence: 99%

Section: Historical Datamentioning

confidence: 99%

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation

Olawaiye

Leath

2019

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…It is estimated that the 5‐year relative survival rate of endometrial cancer is 83.4%, but its survival rate has no significant improvement since the mid‐1970 s 2 . Some studies proved that, in addition to International Federation of Gynecology and Obstetrics (FIGO) stage, demographic and tumor‐related information also had effects on the prognosis of endometrial cancer 3‐5 …”

Section: Introductionmentioning

confidence: 99%

Competing risk nomogram predicting cancer‐specific mortality for endometrial cancer patients treated with hysterectomy

Xie

Yang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe incidence of endometrial cancer has tended to increase in recent years. However, competing risk nomogram combining comprehensive factors for endometrial cancer patients treated with hysterectomy is still scarce. Therefore, we aimed to build a competing risk nomogram predicting cancer‐specific mortality for endometrial cancer patients treated with hysterectomy.MethodsPatients diagnosed with endometrial cancer between 2010 and 2012 were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database. Competing risk model was performed to select prognostic variables to build the competing risk nomogram to predict the cumulative 3‐ and 5‐year incidences of endometrial cancer‐specific mortality. Harrell's C‐index, receiver operating characteristic (ROC) curve, and calibration plot were used in the internal validation. And decision curve analysis was applied to evaluate clinical utility.ResultsA total of 10,447 patients were selected for analysis. The competing risk nomogram identified eight prognostic variables, including age at diagnosis, race, marital status at diagnosis, grade, histology, tumor size, FIGO stage, and number of regional nodes positive. The C‐index of the competing risk nomogram was 0.857 (95% confidence interval [CI]: 0.854–0.859), and the calibration plots were adequately fitted. When the threshold probabilities were between 1% and 57% for 3‐year prediction and between 2% and 67% for 5‐year prediction, the competing risk nomogram was of good clinical utility.ConclusionsA competing risk nomogram for endometrial cancer patients treated with hysterectomy was successfully built and internally validated. It was an accurately predicted and clinical useful tool, which could play an important role in consulting and health care management of endometrial cancer patients.

show abstract

“…Researchers believe that v-NOTES is a protected, efficient, and feasible mildly extensive operation in highly overweighing individuals with initial endometrial tumor when conducted by a professional doctor, and that v-NOTES is a secure, efficient, and viable slightly extensive operation in excessive overweight people with early endometrial tumor. The authors of [ 11 ] examined the effects of adjunctive therapy, sociodemographic variables, and cancer characteristics on the longevity of individuals with non-metastatic simple cell endometrial tumor. In this group from the Norwegian Cancer Center Statistics, adjuvant treatment had no discernible impact on sustainability.…”

Section: Related Workmentioning

confidence: 99%

Research on the Guiding Effect of CTCs on Postoperative Adjuvant Therapy for Patients with Early Stage Endometrial Cancer

Zhai

Zhang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Endometrial tumor has increased in occurrence and fatality in China during the last 11 years, owing to inconsistent hormone use and modifications in people living surrounding and lifestyles. One of the three main gynaecological tumors is endometrial carcinoma (EC). Longer waiting duration of operation was linked to a lower chance of sustainability in endometrial tumor patients. Despite the great sustainability rate of endometrial tumor, only around 46 percent of patients undergo adjuvant treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating free DNA (cfDNA) are the most investigated tumor noninvasive indicators. These circulating biomarkers are important in the knowledge of metastasis and tumorigenesis, and they could help researchers comprehend how cancer dynamics evolve throughout the therapy and illness development. In patients with solid tumor, the existence of circulating tumor cells (CTCs) in the peripheral blood is linked to a weak prognosis. However, there is a scarcity of information on how to detect CTCs in endometrial cancer (EC). Hence, in this paper, we analyze the guiding effect of CTCs on postoperative adjuvant treatment for sufferers with initial phase endometrial tumor using multi-cox regression method. The dataset is selected and the blood samples are collected using plasma separation method. The CTC is detected using differential diagnosis. The morphology and biological features, Immunocytochemistry, Genomic analysis, Transcriptomic analysis, Proteomic analysis, and molecular analysis are performed and the outcomes are evaluated.

show abstract

Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database

Cited by 21 publications

References 36 publications

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation

Competing risk nomogram predicting cancer‐specific mortality for endometrial cancer patients treated with hysterectomy

Research on the Guiding Effect of CTCs on Postoperative Adjuvant Therapy for Patients with Early Stage Endometrial Cancer

Contact Info

Product

Resources

About